Best way to predict recurrence in patients with triple-negative breast cancer

Molecular testing for minimal residual disease is a powerful stratification tool in patients with early stage, triple-negative breast cancer, according to Milan Radovich, PhD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, and colleagues.

They presented groundbreaking results from their study focused on assessing the ability of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) to predict recurrence in women with early stage triple-negative breast cancer. While ctDNA is a sensitive predictor of minimal residual disease, CTC provides complementary results. Combining ctDNA and CTC may provide vital information in stratifying the risks of recurrence in these women.

These results were shared at SABCS 2019.